Peter J. Reddig

Array ( [id] => 15631941 [patent_doc_number] => 10588938 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-17 [patent_title] => Receptor-based antagonists of the programmed cell death 1 (PD-1) pathway [patent_app_type] => utility [patent_app_number] => 15/723048 [patent_app_country] => US [patent_app_date] => 2017-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 23966 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15723048 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12660505 [patent_doc_number] => 20180112001 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-26 [patent_title] => Anti-MUC16 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind MUC16 and CD3, and Uses Thereof [patent_app_type] => utility [patent_app_number] => 15/713574 [patent_app_country] => US [patent_app_date] => 2017-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43825 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15713574 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14743983 [patent_doc_number] => 20190255165 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of Cancer [patent_app_type] => utility [patent_app_number] => 16/331398 [patent_app_country] => US [patent_app_date] => 2017-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 75020 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -114 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16331398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17393403 [patent_doc_number] => 11242405 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-08 [patent_title] => Monoclonal antigen-binding proteins to intracellular oncogene products [patent_app_type] => utility [patent_app_number] => 15/710384 [patent_app_country] => US [patent_app_date] => 2017-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 9989 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15710384 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17393403 [patent_doc_number] => 11242405 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-08 [patent_title] => Monoclonal antigen-binding proteins to intracellular oncogene products [patent_app_type] => utility [patent_app_number] => 15/710384 [patent_app_country] => US [patent_app_date] => 2017-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 9989 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15710384 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15696831 [patent_doc_number] => 10604583 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-31 [patent_title] => Anti-CD276 polypeptides, proteins, and chimeric antigen receptors [patent_app_type] => utility [patent_app_number] => 15/699419 [patent_app_country] => US [patent_app_date] => 2017-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 16588 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15699419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16290347 [patent_doc_number] => 10767184 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-08 [patent_title] => Chimeric antigen receptors targeting B-cell maturation antigen [patent_app_type] => utility [patent_app_number] => 15/692473 [patent_app_country] => US [patent_app_date] => 2017-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 39 [patent_no_of_words] => 14291 [patent_no_of_claims] => 59 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15692473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13717943 [patent_doc_number] => 20170369926 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => NEW MARKERS FOR EARLY DIAGNOSIS OF OVARIAN CANCER, MONITORING DURING THERAPY, AND NEW THERAPY OPTIONS DURING AND AFTER CHEMOTHERAPY [patent_app_type] => utility [patent_app_number] => 15/690957 [patent_app_country] => US [patent_app_date] => 2017-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8691 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15690957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12702490 [patent_doc_number] => 20180125996 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => ANTIBODY DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 15/690737 [patent_app_country] => US [patent_app_date] => 2017-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51958 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15690737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15816967 [patent_doc_number] => 10633650 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-28 [patent_title] => Expression and secretion system [patent_app_type] => utility [patent_app_number] => 15/690544 [patent_app_country] => US [patent_app_date] => 2017-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 23 [patent_no_of_words] => 20129 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 152 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15690544 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13314279 [patent_doc_number] => 20180208676 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => Androgen Suppression, Prostate-Specific Membrane Antigen and the Concept of Conditionally Enhanced Vulnerability [patent_app_type] => utility [patent_app_number] => 15/688021 [patent_app_country] => US [patent_app_date] => 2017-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4270 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15688021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13689643 [patent_doc_number] => 20170355776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-14 [patent_title] => USE OF CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS TO TREAT CANCER [patent_app_type] => utility [patent_app_number] => 15/685670 [patent_app_country] => US [patent_app_date] => 2017-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19499 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15685670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18667551 [patent_doc_number] => 11774442 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-03 [patent_title] => Molecule sensor systems [patent_app_type] => utility [patent_app_number] => 16/325650 [patent_app_country] => US [patent_app_date] => 2017-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 49 [patent_no_of_words] => 25723 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16325650 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14467831 [patent_doc_number] => 20190185558 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => ANTIBODIES DIRECTED AGAINST SIGNAL PEPTIDES, METHODS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/676892 [patent_app_country] => US [patent_app_date] => 2017-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16736 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15676892 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17635032 [patent_doc_number] => 11345745 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-31 [patent_title] => Peptide-hinge-free flexible antibody-like molecule [patent_app_type] => utility [patent_app_number] => 15/670641 [patent_app_country] => US [patent_app_date] => 2017-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 10418 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 181 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15670641 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12178689 [patent_doc_number] => 20180037625 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'USE OF THE CD2 SIGNALING DOMAIN IN SECOND-GENERATION CHIMERIC ANTIGEN RECEPTORS' [patent_app_type] => utility [patent_app_number] => 15/669562 [patent_app_country] => US [patent_app_date] => 2017-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 24997 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15669562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12983686 [patent_doc_number] => 20170343556 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-30 [patent_title] => HISTOCHEMICAL ASSAY FOR EVALUATING EXPRESSION OF PROGRAMMED DEATH LIGAND 1 (PD-L1) [patent_app_type] => utility [patent_app_number] => 15/663640 [patent_app_country] => US [patent_app_date] => 2017-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13266 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 178 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15663640 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12151532 [patent_doc_number] => 20180022795 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-25 [patent_title] => 'TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY' [patent_app_type] => utility [patent_app_number] => 15/658115 [patent_app_country] => US [patent_app_date] => 2017-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 51 [patent_no_of_words] => 58136 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15658115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12138253 [patent_doc_number] => 20180016337 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-18 [patent_title] => 'CAR IMMUNE CELLS TO TREAT CANCERS' [patent_app_type] => utility [patent_app_number] => 15/651692 [patent_app_country] => US [patent_app_date] => 2017-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 26876 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15651692 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12030864 [patent_doc_number] => 20170320963 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-09 [patent_title] => 'Genetic Products Differentially Expressed In Tumors And The Use Thereof' [patent_app_type] => utility [patent_app_number] => 15/650092 [patent_app_country] => US [patent_app_date] => 2017-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 57 [patent_no_of_words] => 29825 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15650092 [rel_patent_id] =>[rel_patent_doc_number] =>)